Navigation Links
Breast Cancer Diagnostic and Drug Technologies: Global Markets
Date:8/28/2012

>TABLE 17 MAJOR ISSUES AND CHALLENGES 36

TABLE 18 PHARMACOGENOMICS TESTS IN USE 39

TABLE 19 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE 40

TABLE 20 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE 40

TABLE 21 CLINICALLY RELEVANT BIOMARKERS 40

TABLE 22 APPROVED COMPANION DIAGNOSTICS, 2011 41

TABLE 23 REGULATORY APPROVAL OF THE DIAGNOSTICS PATHWAY 44

TABLE 24 APPROVED CANCER DRUGS, 2011 47

TABLE 25 FACTORS INFLUENCING THE CHOICE OF A DIAGNOSTICS PARTNER 48

TABLE 26 SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM

FOR BREAST CANCER 52

TABLE 27 MAIN TYPES OF BREAST CANCER 52

TABLE 28 BREAST CANCER EVALUATION TESTS 55

TABLE 29 TREATMENT PLAN 56

TABLE 30 HORMONE THERAPY 57

TABLE 31 CANCER STAGES 57

TABLE 32 RISK FACTORS OF RECURRENCE AFTER SUCCESSFUL TREATMENT FOR BREAST

CANCER 58

TABLE 33 BREAST CANCER PREVENTION MEASURES 59

TABLE 34 AMERICAN CANCER SOCIETY'S DIETARY GUIDELINES FOR CANCER PREVENTION 59

TABLE 35 BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008 (THOUSANDS) 63

TABLE 36 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010–2016 65

TABLE 37 NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 (THOUSANDS/%) 66

TABLE 38 EFFECTIVE EDUCATION AND SCREENING ADVANTAGES IN THE U.K. AND THE U.S.

(CASES PER DAY) 67

TABLE 39 CRUDE AND EUROPEAN AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES

PER 100,000 POPULATIONS IN THE U.K., 2008 68

TABLE 40 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS) 68

TABLE 41 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER AND PROJECTIONS,

2010-2016 (THOUSANDS) 69

TABLE 42 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2008–2016 (THOUSANDS) 71

TABLE 43 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016 (THOUSANDS) 72

TABLE 44 JAPAN ESTIM
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
2. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software
3. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
4. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
5. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Volpara Breast Density Software
6. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
7. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
8. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
9. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
10. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
11. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 1, 2011 Reportlinker.com announces that a new market ... Pen Injectors http://www.reportlinker.com/p0369406/Pen-Injectors.html ... increasing number of drugs in pre-filled disposable cartridges and ... the expense of other drug delivery methods such as ...
... Feb. 1, 2011 Reportlinker.com announces that a ... catalogue: Epoetin alfa - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
Cached Medicine Technology:Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Senior drug regulatory ... on June 25 to discuss—for the first time in the ... getting drugs through the regulatory process in a timely manner. ... evaluation will share respective best practices and processes in drug ... Strait panel at the DIA 2013 49th Annual ...
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... Dallas, TX (PRWEB) June 18, 2013 ... Tebbetts, launched his new website, thebestbreast.com, showcasing his ... provides women with information about his surgical method ... , Outlined on his website, Dr. Tebbetts ... Unlike the traditional methods, Dr. Tebbetts’ method does ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:SimuCase avatars advance speech-language pathology training 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: